To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The NCIC Clinical Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Faculty Researchers

Meet the Faculty Researchers


The information contained in this website is intended for use by NCIC Clinical Trials Group members at participating centres.

Recently Activated

  • CLC2 
    A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (> = to 65 years of age) with Chronic Lymphocytic Leukemia (CLL).
  • CLC2E 
    A Prospective Economic Analysis of NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= 65 Years of Age) With Chronic Lymphocytic Leukemia
  • HE1 
    Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
  • I216 
    Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
  • I218 
    A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
  • I219 
    A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
  • LY17 
    A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
  • MA32D 
    Change In Mammographic Density with Metformin Use: A Companion Study to NCIC CTG Study MA.32
  • MA36 
    Adjuvant Olaparib vs Placebo in Patients with BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer
  • MEC4 
    Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
  • PR17 
    Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
  • SC24 
    Phase II Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy for Patients with Spinal Metastases
  • SRC7 
    Sorafenib vs Placebo in Desmoid Tumors or Aggressive Fibromatosis
  • Planned Trials

  • CEC5 
    Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
  • CEC6 
    Radiotherapy with Temozolomide versus Radiotherapy with PCV Chemotherapy for 1p/19q Co-deleted Anaplastic or Low Grade Glioma
  • MAC18 
    POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer
  • MAC19 
    A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy